PDF factsheet

antithrombotics in percutaneous coronary intervention for patients with high residual platelet activity on clopidogrel, clinical trials results

high-dose clopidogrel versus normal-dose clopidogrel
GRAVITAS, 2011 NCT00645918	High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) versus regular clopidogrel dose	patients receiving drug-eluting stents with high residual platelet activity (PRU>=230) on the regular clopidogrel dose (platelet-function tests with the VerifyNow assay 12 to 24 hours after PCI)	open Follow-up duration: 6 months North America

Group by
in first

in second

Order trials by

display ongoing trials

Type of trial

Limit to tags

Exclude tags